Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 2, 2009, Pages 386-393

  Provenzano, Robert ^a   Schiller, Brigitte ^b   Rao, Madhumathi ^c   Coyne, Daniel ^d   Brenner, Louis ^e,f   Pereira, Brian J G ^f  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b CA   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f AMAG PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; FERUMOXYTOL; HEMOGLOBIN; IRON; TRANSFERRIN; MAGNETITE;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; AGED; BLOOD; CHRONIC DISEASE; COMPARATIVE STUDY; DIET SUPPLEMENTATION; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANEMIA, IRON-DEFICIENCY; CHRONIC DISEASE; DIETARY SUPPLEMENTS; FEMALE; FERRITINS; FERROSOFERRIC OXIDE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY DISEASES; MALE; MIDDLE AGED; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 66849104249     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02840608     Document Type: Article

References (34)

1. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ: Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10: 1793 - 1800, 1999
2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162: 1401-1408, 2002
3. Hsu CY, McCulloch CE, Curhan GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 13: 2783-2786, 2002
4. Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 19: 161-167, 2006 (Pubitemid 44420105)
5. Fishbane S, Maesaka JK: Iron management in end-stage renal disease. Am J Kidney Dis 29: 319-333, 1997 (Pubitemid 27106553)
6. Kooistra MP, Niemantsverdriet EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ: Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 13: 82-88, 1998 (Pubitemid 28033584)
7. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41-46, 1995
8. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996 (Pubitemid 26364277)
9. Using iron agents. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S58-S70, 2006
10. Macdougall IC: Strategies for iron supplementation: Oral versus intravenous. Kidney Int Suppl 69: S61-S66, 1999 (Pubitemid 29113585)
11. Danielson BG: Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 15(Suppl 2): S93-S98, 2004 (Pubitemid 39578822)
12. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28: 529-534, 1996 (Pubitemid 26337591)
13. Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int 21: 290-295, 2001 (Pubitemid 32734437)
14. Macdougall IC, Roche A: Administration of intravenous iron sucrose as a 2-minute push to CKD patients: A prospective evaluation of 2,297 injections. Am J Kidney Dis 46: 283-289, 2005
15. Data on file. Cambridge MA, AMAG Pharmaceuticals, Inc.
16. Jacobs P, Lewis J, Frigo T: Bleomycin detectable iron and percent transferrin saturation in the serum of patients receiving either ferumoxytol, iron gluconate or iron sucrose. J Am Soc Nephrol 15: 546A, 2004
17. Lewis J, Jacobs P, Frigio T: Comparison of free iron in ferumoxytol with other iron therapeutics. J Am Soc Nephrol 14: 771A, 2003
18. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK: Pharmacokinetic study of ferumoxytol: A new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 25: 400-410, 2005 (Pubitemid 41160999)
19. Spinowitz BS, Schwenk MH, Jacobs PM, Bolton WK, Kaplan MR, Charytan C, Galler M: The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 68: 1801-1807, 2005
20. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ: Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 19: 1599-1605, 2008
21. Menth M, Rockel A, Abdelhamid S, Fiegel P, Walb D: Low-molecular-weight protein-permeable cuprammonium rayon haemofilter. Nephrol Dial Transplant 7: 844-847, 1992
22. Eschbach JW: Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol 18: 347-361, 2005
23. Besarab A: Resolving the paradigm crisis in intravenous iron and erythropoietin management. Kidney Int Suppl 101: S13-S18, 2006
24. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11: 530-538, 2000 (Pubitemid 30115083)
25. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study. J Am Soc Nephrol 18: 975-984, 2007 (Pubitemid 46434515)
26. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19: 372-379, 2008 (Pubitemid 351240658)
27. Lenga I, Lok C, Marticorena R, Hunter J, Dacouris N, Goldstein, M: Role of oral iron in the management of long-term hemodialysis patients. Clin J Am Soc Nephrol 2: 5, 2007
28. Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L: Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 52: 907-915, 2008
29. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 19: 561-565, 2004 (Pubitemid 38263113)
30. Venofer [Package insert]. American Regent, Inc., Shirley, NY, 2005
31. Ferrlecit [Package insert]. Watson Pharma, Inc., Corona, CA, 2006
32. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
33. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
34. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH: Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: 141-149, 2004 (Pubitemid 38072625)